These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12578487)

  • 1. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure.
    Shyu KG; Cheng JJ; Kuan P
    J Am Coll Cardiol; 2002 Oct; 40(8):1383-8. PubMed ID: 12392825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.
    Tepel M; van der Giet M; Schwarzfeld C; Laufer U; Liermann D; Zidek W
    N Engl J Med; 2000 Jul; 343(3):180-4. PubMed ID: 10900277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity.
    Sandhu C; Belli AM; Oliveira DB
    Cardiovasc Intervent Radiol; 2006; 29(3):344-7. PubMed ID: 16502177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?
    Kefer JM; Hanet CE; Boitte S; Wilmotte L; De Kock M
    Acta Cardiol; 2003 Dec; 58(6):555-60. PubMed ID: 14713182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).
    Diaz-Sandoval LJ; Kosowsky BD; Losordo DW
    Am J Cardiol; 2002 Feb; 89(3):356-8. PubMed ID: 11809444
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial.
    Burns KE; Chu MW; Novick RJ; Fox SA; Gallo K; Martin CM; Stitt LW; Heidenheim AP; Myers ML; Moist L
    JAMA; 2005 Jul; 294(3):342-50. PubMed ID: 16030279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcysteine and renal function following coronary angiographic procedures.
    Bagshaw SM; Culleton BF
    JAMA; 2003 Jun; 289(21):2795; author reply 2796. PubMed ID: 12783908
    [No Abstract]   [Full Text] [Related]  

  • 17. Acetylcysteine and renal function following coronary angiographic procedures.
    Balderramo DC
    JAMA; 2003 Jun; 289(21):2795-6; author reply 2796. PubMed ID: 12783907
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcysteine and contrast agent-associated nephrotoxicity.
    Briguori C; Manganelli F; Scarpato P; Elia PP; Golia B; Riviezzo G; Lepore S; Librera M; Villari B; Colombo A; Ricciardelli B
    J Am Coll Cardiol; 2002 Jul; 40(2):298-303. PubMed ID: 12106935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.